Allan Pereira, GI Medical Oncologist and Researcher, Associate Member at Moffitt Cancer Center, shared on X:
” TALENTACE – Lancet Gastroenterology and Hepatology
Phase 3, 40 centers across China and Japan
- n=342, untreated TACE-eligible HCC
- On-demand TACE + atezolizumab/bevacizumab vs TACE alone
- TACE-PFS 11.30 vs 7.03 mo, HR 0.71 (95% CI 0.55 – 0.92), p=0.0089
- OS at first interim 34.53 vs 35.38 mo, HR 0.96 – immature
The first Phase 3 to win on its primary endpoint, but it was TACE-PFS: time to unTACEable/untreatable progression, TACE failure/refractoriness, or death.
It was not the conventional RECIST-based PFS used by the other trials.. Let alone OS.
TACE-PFS bundles local progression with re-treatment need, and the survival curves are still superimposed. We want the OS gain.
However, alongside EMERALD-1, LEAP-012, and CARES-005, all four trials point to the same core conclusion: adding an ICI + anti-VEGF to TACE significantly improves disease control compared with TACE alone, but none has yet demonstrated a statistically significant OS benefit.
Title: On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
Authors: Masatoshi Kudo, Sadahisa Ogasawara, Ruibao Liu, Shanzhi Gu, Kunyuan Wang, Ming Zhao, Hongtao Hu, Zhaoyu Liu, Kecan Lin, Jingfeng Liu, Zhengyu Lin, Yonghong Zhang, Tao Peng, Jinhua Song, Makoto Ueno, Jiye Zhu, Lidan Bai, Lin Tong, Yanjun Shi, Guohong Han, Jiahong Dong.
Read The Full Article.”
You can also read: Atezolizumab Plus Bevacizumab in Child-Pugh B Hepatocellular Carcinoma
